Aug 2026· International Journal of Molecular Sciences· Vol 27, pp. 7107· 0 citations· 133 references
Medicine
TL;DR
Recently investigated natural compounds with anti-breast cancer activity are discussed, ranging from polyphenols, terpenoids, alkaloids, sulfur-containing compounds and the emerging plant-derived extracellular vesicles, supporting their potential use in breast cancer therapy.
Abstract
Breast cancer (BC) is the most frequently diagnosed malignancy and generally the leading cause of cancer-related mortality among women worldwide. Molecular targeted therapies, including endocrine treatment for hormone-responsive tumors, anti-HER2 agents for HER2-positive tumors and PARP inhibitors (PARPis) for homologous recombination-deficient (HRD) tumors, have significantly improved patient outcomes, but several clinical challenges are still open. The development of acquired resistance strongly limits the long-term efficacy of current treatment strategies, underscoring the necessity to identify novel therapeutic approaches for breast cancer therapy. In this review, we summarize and discuss recently investigated natural compounds with anti-breast cancer activity, ranging from polyphenols, terpenoids, alkaloids, sulfur-containing compounds and the emerging plant-derived extracellular vesicles. We focus on their ability to induce DNA damage or oxidative stress, modulating the DNA damage response (DDR) and interfering with key oncogenic signaling pathways. We also discuss the potential of these compounds to enhance the efficacy of conventional therapies, thereby offering a promising role in overcoming clinical resistance. Despite clinical relevance remains under development and further studies are required; many of the natural compounds examined here appear to effectively target DDR signaling and oncogenic pathways, supporting their potential use in breast cancer therapy.
In vitro and in vivo breast cancer models show that CBP inhibition disrupts DNA repair and cell-cycle regulatory pathways, thereby enhancing doxorubicin-induced cytotoxicity and apoptosis, and support a rational epigenetic-chemotherapy combination approach.
Wafaa S. Ramadan, Iman M. Talaat, A. Al-Azawi et al.· Translational Research: The...· 0 citations
Cancer drug resistance remains a major challenge in oncology, limiting the long-term effectiveness of chemotherapy, targeted therapies, and immunotherapy. Resistance arises through multiple interconnected mechanisms, including overexpression of ATP-binding cassette (ABC) transporters, activation of pro-survival signali...
Manjot Singh, Saurabh Singh, Kalpana Rahate et al.· Mini-Reviews in Medical Chem...· 0 citations
PARP inhibitors have become an integral component of treatment strategies for advanced epithelial ovarian cancer, particularly in BRCA1/2-mutated and homologous recombination-deficient (HRD) tumors. Despite clinically meaningful improvements in progression-free survival, a substantial proportion of patients develop pri...
D. Incognito, G. Ciappina, G. Ettore et al.· Frontiers in Oncology· 0 citations
This review uncovers recent updates on acquired resistance mechanisms toward standard-of-care treatments driven by deeply rooted heterogeneity and aggressive nature and helps to identify novel strategies targeting pathways to reverse resistance and reduce toxicity in breast cancer patients.
Anuveda Sree Samudrala, G. Nagaraju, RamaRao Malla· Biochimica et biophysica act...· 0 citations
Triple-negative breast cancer (TNBC) remains one of the most therapeutically challenging malignancies because of its pronounced molecular heterogeneity, aggressive progression, and frequent development of resistance to chemotherapy, targeted agents, and immunotherapy. Natural products offer a distinctive medicinal chem...
Hadir M. Emara, Nageh K. Allam· RSC Medicinal Chemistry· 0 citations
Poly(ADP-ribose) polymerase inhibitors (PARPis) have transformed the treatment landscape of homologous recombination-deficient malignancies, particularly BRCA1/2-mutant breast, ovarian, pancreatic, and prostate cancers. In contrast, clinical studies evaluating PARPis in broadly selected colorectal cancer (CRC) patients...
Mariam Elesnawy, Eman Masood, A. Naik· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.